aysun senturk - Academia.edu (original) (raw)

Papers by aysun senturk

Gazi Medical Journal, 2015

EDTA-dependent pseudothrombocytopenia (EDTA-PTCP) is a phenomenon caused by EDTA-dependent anti-p... more EDTA-dependent pseudothrombocytopenia (EDTA-PTCP) is a phenomenon caused by EDTA-dependent anti-platelet antibody. It is necessary for clinicians to consider the possible presence of PTCP in cases of patients having low platelet counts without any hemorrhagic tendency. We here present a EDTA-dependent pseudothromboctyopenia case which might be associated with rheumatoid arthritis and/or the medications such as sulfasalazine, leflunomide and methylprednisolone. As a conclusion pseudothrombocytopenia should be excluded in all thrombocytopenic patients without any hemorrhagic tendency by manual peripheric smear to avoid unnecessary diagnostic tests and wrong treatments.

Journal of Immunotherapy and Precision Oncology

International Journal of Hematology-Oncology and Stem Cell Research

Background: The transmembrane receptor tyrosine kinase-like orphan receptor 1 (ROR1) has acted on... more Background: The transmembrane receptor tyrosine kinase-like orphan receptor 1 (ROR1) has acted on the causation and sustentation of mature B cell lymphomagenesis for chronic lymphocytic leukemia (CLL) cells. The aim of this study was to show whether there is a relationship between the level of ROR1 surface expression in CLL cells and disease findings. Materials and Methods: The level of ROR1 cell surface expression was determined in accordance with the flow cytometric analysis of CLL patients at the first diagnosis time. 2 groups were formed according to the high and low ROR1 levels. The cut-off point to the ROR1 level was calculated for advanced-stage disease by using receiver operating characteristic (ROC) curves. A two-sided p-value <0,05 was considered statistically significant. Results: 108 CLL cases with a median age of 60 were enrolled. The median percentage of ROR1 cell surface marker positivity in the CD5/CD19 positive leukemic cell was 62%. The CLL cases with high ROR1...

Mediterranean Journal of Hematology and Infectious Diseases

Objectives: Patients with hematologic malignancies have a high risk of coronavirus disease 2019 (... more Objectives: Patients with hematologic malignancies have a high risk of coronavirus disease 2019 (COVID-19) mortality. This study aimed to investigate the impact of COVID-19 on mortality rates in patients with various hematologic malignancies and to determine risk factors associated with all-cause mortality. Methods: A multi-center, observational retrospective analysis of patients with hematologic malignancies infected with COVID-19 between July 2020 and December 2021 was performed. Demographic data, clinical characteristics, and laboratory parameters were recorded. Patients were grouped as non-survivors and survivors. All-cause mortality was the primary outcome of the study. Results: There were 569 patients with a median age of 59 years. Non-Hodgkin lymphoma (22.0%) and multiple myelomas (18.1%) were the two most frequent hematologic malignancies. The all-cause mortality rate was 29.3%. The highest mortality rates were seen in patients with acute myeloid leukemia (44.3%), acute lymp...

medical journal of islamic world academy of sciences, 2018

Chronic lymphocytic leukemia (CLL) is a chronic lymphoproliferative hematological malignancy acco... more Chronic lymphocytic leukemia (CLL) is a chronic lymphoproliferative hematological malignancy accompanied by a monoclonal proliferation of mature B lymphocytes. CLL is the most common type of adult leukemia with 5/100,000 incidence rate every year in Western countries (1-3). CLL is a disease that mostly affects elder; 80% of the patients are aged more than 50 years (4,5). However, CLL has a heterogeneous course according to the clinical and molecular characteristics (6,7).

Aim: The aim is to investigate retrospectively the association between vitamin B12 levels at the ... more Aim: The aim is to investigate retrospectively the association between vitamin B12 levels at the time of diagnosis and the complications including hypercalcemia and fractures in multiple myeloma patients. Material and Method: The association between vitamin B12 level at the time of diagnosis and myeloma complications such as hypercalcemia and bone lesions were analyzed with chi-square in 140 multiple myeloma patients. Findings: Vitamin B12 deficiency was found in 29 patients (20.7%). While the rate of hypercalcemia is 37.9% in patients with vitamin B12 deficiency, it is 18.9% in patients without deficiency. The fracture rate was 44.8% in vitamin B12 deficient group and 23.4% in the other group. Results: Vitamin B12 deficiency at the time of diagnosis is associated with hypercalcemia and bone fracture rate (p=0.04, p=0.03). Discussion: Vitamin B12 level might have prognostic significance since hypercalcemia and fracture rate is increased in the vitamin B12 deficient group. Further st...

Acta Oncologica Turcica, 2021

Introduction: This study aims to determine the changes in and the factors related to the bone min... more Introduction: This study aims to determine the changes in and the factors related to the bone mineral density in patients with bcr/abl-negative chronic myeloproliferative neoplasm (cmpd). Methods: The data of 38 males (52.1%) and 35 females (47.9%) patients diagnosed with cmpd were analyzed retrospectively. The age, gender, diagnosis (polycythemia vera (pv), essential thrombocythemia (et)), jak2v617f mutation positivity, the presence of the cmpd complications and the bone mineral densitometry (bmd) measurements of femur neck and lumbar spine carried out during the diagnosis were recorded for each patient. The patients were divided into four groups: under 65 and over 65 years old for men, premenopausal and postmenopausal status for women. They were also grouped according to the t score of the femur neck and lumbar spine with normal and decreased bone density. Results: Female patients were found to have more bone loss in the lumbar spine (p=0.031). In female patients, the reduction in the lumbar spine bmd was greater in the postmenopausal group (p=0.012). The decrease in bone density in the femur neck was found to be greater in the group above 65 years of age (p=0.01). There was no relationship between bmd and et, pv, jak2v617f mutation positivity, and cmpd complications such as thrombosis and hemorrhage. Discussion and conclusion: according to the results obtained in our study, the presence of cmpd increases bone loss in lomber area in female patients. Therefore, the bmd measurement and calcium-d supportive treatment planning in the premenopausal group are thought to be beneficial in female patients.

International Journal of Hematology-Oncology and Stem Cell Research, 2020

Background: Complete response (CR) and very good partial response (VGPR) are targeted with pre-AS... more Background: Complete response (CR) and very good partial response (VGPR) are targeted with pre-ASCT induction regimens in patients by diagnosed multiple myeloma (MM), who are candidates for ASCT. In this study, it was aimed to compare the response and survival evaluations of cases who underwent induction treatment by vincristine-doxorubicin-dexamethasone (VAD) protocol versus bortezomib containing regimens. Materials and Methods: The data of 96 ASCT eligible patients, retrospectively analyzed. P value> 0.05 was considered statistically significant. Results: While 66 cases had received bortezomib containing regimens as induction regimen, 30 cases had received VAD protocol. The total survival was 91.3 (st.s 6) months and 43 (st.s 7.9) months, respectively, when we compared the cases without ASCT and with ASCT (p = 0.001). The OS of patients who underwent ASCT after reaching at least VGPR was longer than the underwent ASCT without reaching VGPR (p=0.019). Post-ASCT PFS (p=0.717) an...

Bratislava Medical Journal, 2020

INTRODUCTION: Myelodysplastic syndromes (MDS) include various hematologic abnormalities character... more INTRODUCTION: Myelodysplastic syndromes (MDS) include various hematologic abnormalities characterized by chronic cytopenia due to disruption in cellular differentiation. This study aims to evaluate the prognostic value of PLR in patients with MDS. MATERIAL AND METHODS: Clinical-laboratory fi ndings and the results of bone marrow biopsies of MDS patients before treatment were recorded. p value of < 0.05 was considered statistically signifi cant. SPSS version 20.0 was used for statistical analysis. RESULTS: The study included 62 patients with median follow-up time of 62.8 ± 4.5 months and median age of 68.5 years. In 13 patients, acute leukemia was transformed. In these subjects, a PLR cutoff level of 46 was established for mortality (p = 0.015). We found a signifi cant relationship between PLR and multilineage series with the presence of dysplasia (p = 0.017). The survival analysis showed a decreased survival in cases with dysplasia in two and/or more series, transformation into acute leukemia, and thrombocytopenia. CONCLUSION: Our study demonstrated that there was a relationship between PLR and MDS with multilineage dysplasia (mld-MDS). PLR is investigated as an infl ammatory fi nding in various hematologic malignancies. Further studies investigating the value of PLR in MDS are needed to determine whether PLR may be a marker of bone marrow dysplasia grading (Tab. 2, Fig. 4, Ref. 32).

Archives of the Balkan Medical Union, 2018

Le sexe masculin et le diamètre tumoral sont des facteurs de risque indépendants pour une maladie... more Le sexe masculin et le diamètre tumoral sont des facteurs de risque indépendants pour une maladie persistante dans le cancer thyroïdien différencié Contexte Le cancer différencié de la thyroïde (CDT) est l'un des néoplasmes les plus rencontrés à ce jour. La récurrence du CDT a été préalablement déclarée comme dépendante des caractéristiques de la tumeur, de la taille de la tumeur, de l'existence d'une métastase ganglionnaire, de la présence d'une invasion extra thyroïdienne, de la présence de métastases à distance, des oncogènes comme des proto-oncogènes B-raf, de l'âge et du sexe masculin. Cependant la plupart des études ont échoué à associer la grande partie de ces données avec la récurrence. L'objectif de l'etude a été d'évaluer la relation entre certaines constatations histopathologiques et morphologiques et la récurrence du cancer de la thyroïde ou la maladie persistante dans une cohorte de 393 patients atteints de CDT. Méthodes Nous avons rétrospectivement analysé 393 patients ayant le diagnostic de CDT entre janvier 2000 et décembre 2010. Résultats L'analyse histopathologique a indiqué le carcinome papillaire chez 362 (%92,1) sujets et

LLM Dergi, 2019

Kas kitlesinde azalmanın, birçok solid tümörde kötü klinik sonuçlar için bağımsız bir belirleyici... more Kas kitlesinde azalmanın, birçok solid tümörde kötü klinik sonuçlar için bağımsız bir belirleyici olduğu bildirilmiştir. Çalışmamızda, Hodgkin lenfoma (HL) hastalarında kemoterapinin kas kitlesi üzerindeki etkisini araştırmayı amaçladık. Hastalar ve Yöntem: Çalışmaya 37 yeni tanı HL hastası dahil edildi. Hastalara adriamisin, bleomisin, vinblastin, dakarbazin (ABVD) kemoterapisi intravenöz olarak verildi. Tedavi öncesi ve dört kür tedavi sonrası çekilen bilgisayarlı tomografi (BT) görüntüleri hastanemizin görüntü arşivleme ve iletişim sisteminde (PACS) mevcuttu. Aksiyal BT'de L3 vertebra belirlendi ve posterior paravertebral kasların bilateral manuel olarak sınırları çizildi. L3 vertebradan geçen kesitle posterior paravertebral kas alanları ve yağsız kitlesi ölçüldü. Bulgular: Hastaların ortanca yaşı 41 (19-76) ve kadın/erkek oranı 26/11 idi. Tanı anında hastaların 18'i erken evre, 19'u ileri evre idi. Başlangıç tedavisi sonrası hastaların 24'ünde parsiyel yanıt, 10'unda tam yanıt, 3'ünde progresyon izlendi. Paravertebral kas alanının tedavi ile değişimi incelendiğinde; hem erken hem de ileri evre hastalıkta dört kür tedavi sonrası istatistiksel anlamlı olarak kas alanında azalma olduğu saptandı. Tam yanıt, parsiyel yanıt ve progresyon gözlenen hastaların bazal kas ölçümünde ise anlamlı fark saptanmadı (p= 0.44). Yanıta göre alt gruplar incelendiğinde tam ve parsiyel yanıt veren hastalarda kemoterapi sonrası istatistiksel anlamlı paravertebral kas alanında azalma saptanırken, progresyon saptanan hastalarda ise kas kitlesi belirgin azalmakla birlikte istatistiksel anlamlılığa ulaşmadı (sırasıyla p değeri 0.028, 0.002 ve 0.18). Sonuç: HL'li hastalarda kemoterapi sonrası kas kitlesinde anlamlı azalma olmuştur. Bu azalma, tedaviye yanıtla ilişkili gözükmekle birlikte daha fazla sayıda olgu ile yapılacak çalışmalara ihtiyaç vardır.

Journal of Cancer Research and Therapeutics, 2018

Plasma cell leukemia (PCL) is a rare and an aggressive form of plasma cell dyscrasias. We report ... more Plasma cell leukemia (PCL) is a rare and an aggressive form of plasma cell dyscrasias. We report a 67-year-old male with PCL which developed while on imatinib mesylate (IM) therapy 38 months after diagnosis of chronic myeloid leukemia (CML). The patient has been treated successfully with bortezomib, melphalan and prednisolone. To our knowledge, only one case of PCL superimposed on Philadelphia positive CML has been reported in the literature and this was before the IM era.

Malaysian Journal of Medical Sciences, 2020

Introduction: Vitamin D, which is known for its effects on calcium and bone metabolism, has recen... more Introduction: Vitamin D, which is known for its effects on calcium and bone metabolism, has recently been associated with haematological malignancies. We aimed to investigate the relationship between disease findings and vitamin D deficiency in essential thrombocythemia (ET) and polycythemia vera (PV). Material and Methods: This retrospective cohort study conducted in Turkey included 73 patients diagnosed with PV or ET according to WHO criteria between 2012 and 2018. Vitamin D deficiency was defined as 25-OH vitamin D < 20 ng/mL. Polymerase chain reaction (PCR) was used to detect the Janus kinase 2 (JAK2) V617F mutation. Results: Vitamin D deficiency was found in 66.7% of PV and 74.2% of ET patients. The median follow-up time of ET and PV patients was 48 months and 47 months, respectively. Patients with the JAK2 mutation had a higher prevalence of a history of thrombosis and age older than 65 years. There was a significant relationship between JAK2 positivity and vitamin D deficiency. Conclusion: There was a remarkably higher prevalence of vitamin D deficiency in JAK2 mutation-positive ET and PV patients. These patients should be carefully evaluated for vitamin D deficiency. More studies are required to further investigate the association between JAK2 and vitamin D.

Clinical Lymphoma Myeloma and Leukemia, 2020

We investigated the effect of PD-1, PD-L1, and EBV positivity on prognosis at the initial diagnos... more We investigated the effect of PD-1, PD-L1, and EBV positivity on prognosis at the initial diagnosis of classic Hodgkin lymphoma. Our data suggest a correlation between PD-L1 positivity and EBV positivity in tumor RS cells, which are also associated with extranodal involvement, intermediate and high international prognostic index score, presence of B symptoms, and advanced-stage disease. Background: The programmed death receptor (PD-1) and ligand (PD-L1) pathway act by suppressing the antitumor response in chronic Hodgkin lymphoma (cHL). In this study, we aimed to investigate the effect of PD-1, PD-L1, and Epstein-Barr virus (EBV) positivity on prognosis at the initial diagnosis of cHL. Material and Methods: Thirty-six patients with cHL were retrospectively analyzed. PD-L1 staining was performed for RS cells and tumor microenvironment in the biopsy materials of cases. The presence of EBV was investigated by EBER (EBV-encoded RNA) method in tumor cell. P < .05 was accepted as significant. Results: The presence of advanced-stage disease, B symptoms, intermediate or high-risk international prognostic index (IPS), and extranodal involvement were found to be related to both PD-L1 positivity and EBV positivity in RS cells. PD-L1 positivity in RS cells was also associated with EBV positivity. There were 6 (16.7%) triple-positive (EBV þ , RS-PD-L1 þ , mic-PD-1 þ) patients. All of these patients had advanced-stage disease, B symptoms at the time of diagnosis, and intermediate-high IPS score, and 4 of 6 patients had extranodal involvement. This group also had significantly shortened overall survival compared with others (38.4 months vs. 67.9 months P ¼ .024). Conclusion: Our data suggest that there is correlation between PD-L1 positivity and EBV positivity in tumor RS cells that are also associated with extranodal involvement, intermediate and high IPS score, presence of B symptoms, and advanced-stage disease. In addition, we identified a group of triple-positive (EBV þ , RS-PD-L1 þ , mic-PD-1 þ) cHL patients who have a very high-risk disease.

Acta Oncologica Turcica, 2019

Teröpotik plazma değişimi (TPD) hasta plazmasının büyük kısmının replasman sıvılarıyla değiştiril... more Teröpotik plazma değişimi (TPD) hasta plazmasının büyük kısmının replasman sıvılarıyla değiştirilip hastaya geri verildiği bir işlemdir. TPD işlemi hematolojik, romatolojik, nörolojik ve toksikolojik hastalıklar olmak üzere bir çok hastalıkta primer tedavi yöntemi ya da tedaviyi tamamlayıcı yöntem olarak kullanılır. Günümüzde yoğun bakım ünitelerinde TPD kullanım sıklığı artmıştır. 2010-2017 tarihleri arasında reanimasyon yoğun bakımda TPD uyguladığımız olguların klinik özelliklerini sunmayı amaçladık. YÖNTEM ve GEREÇLER: Atatürk Eğitim ve Araştırma Hastanesi Aferez Ünitesi verileri retrospektif olarak incelenmiştir. Merkezimizde yapılan aferez işlemlerinde Fresenius COM.TEC cihazı kullanılmıştır. Reanimasyon yoğun bakımda takip edilen toplam 41 olgunun yaşı, cinsiyeti, TPD endikasyonu, TPD sayısı, Amerikan Aferez Derneği(ASFA) terapötik aferez kategorisi retrospektif olarak incelendi. 171 TPD işlemi kaydedildi. BULGULAR: Olguların ortanca yaşı 54 (19-88) bulundu. Kadın erkek oranı 19/22 (%46,3/%53,7) di. Replasman sıvısı olarak 171 işlemin 100 tanesinde taze donmuş plazma, 71 tanesinde albümin kullanılmıştır. TPD uygulanan olgular ASFA kategorilerine göre, 8'i kategori 1, 5'i kategori 2, 28'i (68.4%) kategori 3 idi. Suicid nedeniyle 2(%4,9), nörolojik nedenlerle 7 (%17,1), akutkaraciğer yetmezliği-hiperbilluribinemi nedeniyle 14 (%34,1), romatolojik nedenlerle 9 (%22), renal transplant rejeksiyonu nedeniyle 2(%4,9), septik şok nedeniyle de 2(%4,9) olguya TPD işlemi uygulanmıştı. Olguların ortalama yoğun bakımda kalış süreleri 18,7(min-maks/ 2-68), gün, hospitalizasyon süresi ortalama 27(min-maks/5-110) gündü. TPD öncesi ve sonrası ortalama hemoglobin (Hgb): 9,3 g/dl (5,3-18) ve 9,7 g/dl (8,2-14,7), trombosit sayısı: 152.000/mikrol (2000-445.000) ve 167.000 mikrol (10000-480.000), TPD seans sayısı ortalama 4, ortanca 4 (1-17) olarak saptandı. İşlem sırasında mortalite gözlenmedi. İzlemleri sırasında 23 hastanın (%54,8) exitus, 18 hastanın (% 42,9) sağ olduğu belirlendi. TARTIŞMA ve SONUÇ: Bizim merkezimizde TPD işlemi en çok ASFA kategori 3 hasta grubunda uygulanmıştır. Bu grupta TPD ana tedaviyi destekleyicidir ve olgunun durumuna özgün olarak kullanılır. Sonuç olarak; yoğun bakım hastalarında TPD endikasyonlarına bireysel yaklaşım önemlidir ve bilim dalları arasındaki multidispliner iletişim plazmaferez uygulamalarının tamamlayıcı tedavi seçeneği olarak uygulanabilirliğinde artışa neden olabilecektir.

Leukemia Research, 2019

Objective: Multiple myeloma (MM) is characterized by the neoplastic proliferation of a single clo... more Objective: Multiple myeloma (MM) is characterized by the neoplastic proliferation of a single clone of plasma cells producing a monoclonal immunoglobulin. In the last decade the major advance in the management of MM has been the introduction of novel agents Thalidomide, Bortezomib and Lenalidomide into the therapeutic armamentarium. The novel agents along with ASCT have markedly improved the rate of complete remission, which has important implications in overall outcomes. Methodology: We retrospectively analysed the data in patients with multiple myeloma who were transplanted at our centre from 2015 to 2018. Aim was to analyse the influence of pre transplant characteristics and post-transplant treatment modalities on progression free and overall survival. Results: A total of 50 MM patients with median age of 55 yrs (38 to 67 years) were transplanted between 2015 and 2018. Male to female ratio was 1.27:1 with 28 (56%) male and 22 (44%) females. In all, 38 (76%) patients had IgG, 7 (14%) had IgA and 2 (4%) had light chain. Twelve (24%) patients were classified as ISS I whereas 25 (50%) were ISS II and 13 (26%) were ISS III. At the time of ASCT, 34 (68%) of patients were in complete remission (CR), 14 (28%) in very good partial remission (VGPR) and 2 (4%) patients were in partial remission (PR). Prior to autograft, 76% (38) of cases had received VTD regimen whereas 24% (28) had received VCD regimen. Conditioning with melphalan 200 mg/ m 2 was given in 44 (88%) of patients, remaining 6 (12%) patients received 140 mg/m 2 in view of renal failure. Following ASCT 48 (96%) patients achieved CR/VGPR at 3 months excluding 2 (4%) patients who had TRM. All patients were advised at 3 months post-transplant for maintenance therapy with thalidomide/lenalidomide. Over a median follow up period of 46 months, 28 (56%) of the patients were alive and disease free, 11 (22%) were alive with relapse, and 9 (18%) had disease related mortality. Median OS and PFS from the date of transplantation were 40 and 26 months respectively. Median OS from diagnosis was 46 months. Conclusion: Autologous stem cell transplantation in combination with novel drugs is an effective strategy in patients with MM to improve depth of response, PFS, and overall survival.

Global Journal of Transfusion Medicine, 2019

Introduction: Pretransfusion testing is an essential serological test to protect the recipient fr... more Introduction: Pretransfusion testing is an essential serological test to protect the recipient from hemolysis and provide compatible blood product. The final step is the crossmatching test which is done by the transfusion center. Although all products are crossmatched in same cases, compatible products may not be available. Aims and Objectives: This study aimed to determine the safety and efficacy of the least incompatible crossmatched erythrocyte transfusion, through the use of biological in vivo crossmatch testing. Materials and Methods: The study included twenty patients who required transfusion and for whom appropriate red blood cell (RBC) could not be found. Totally, 69 units of least incompatible RBC transfusion from crossmatch incompatible products was administered by applying the “in vivo compatibility” test. Patients were observed during the transfusion with respect to acute hemolytic reactions that could develop. The biochemical hemolysis parameters were examined before and at 24 h after transfusion. Results: All transfusions were completed successfully with no complications or symptoms observed in any case. A statistically significant increase in hematocrit (Hct) and hemoglobin was seen post transfusion (P < 0.001). As parameters of hemolysis, lactate dehydrogenase and bilirubin levels were found to be statistically normal (not increased) (P = 0.453 and 0.946, respectively). Conclusions: Biological in vivo compatibility testing seems to be a safe, predictive, and bedside feasible test, which could be lifesaving for many patients.

Indian Journal of Hematology and Blood Transfusion, 2019

Chronic lymphocytic leukemia (CLL) is a common hematological malignancy. This study is aimed to i... more Chronic lymphocytic leukemia (CLL) is a common hematological malignancy. This study is aimed to investigate the prognostic effect of clinic, laboratory and flow cytometric analysis in CLL patients. Newly diagnosed 55 CLL cases were divided into two groups, as stable disease (Group 1) and progressive disease (Group 2). Group 1 included those who did not require any treatment since diagnosis and those who did not progress after receiving the first step anti CLL treatment. Group 2 included the patients who received C 2 steps treatment. The relation between the two groups was analyzed statistically in terms of clinical, laboratory and flow cytometric findings. Twenty patients (36.3%) required treatment at the time of diagnosis, four patients (3.8%) received first-line treatment during follow-up and 31 (56.3%) patients were followed without any treatment. Thirteen patients required second step treatment after a median of 26.3 months. The risk of progression was found to be increased 5-fold (p = 0.015) in the CD38 positive patient group, 4.2-fold (p = 0.0147) in the FMC7 negative patient group and 2.8-fold in the CD11c negative patient group. FMC 7 negativity decreased total survival 5.9-fold (p = 0.051). Unlike similar publications, we found that patients with CD11c or FMC7 negativity were in a higher need for C 2 step treatment. This suggests that CD11c or FMC7 negativity may be used as a poor prognostic marker in CLL.

Journal of Medical Biochemistry, 2019

Summary Background This study aimed to show the status of thioldisulphide homeostasis in essentia... more Summary Background This study aimed to show the status of thioldisulphide homeostasis in essential thrombocytosis patients, which is known to play a role in platelet function. Methods The study included 27 ET patients and a control group of 36 healthy subjects. Serum total (–SH + –S–S–) and native (–SH) thiol levels were measured in all subjects using an automatic method. Results Age and gender distribution were similar in both groups. Compared with the control group, in the ET group, there were increased native thiol and total thiol levels (p = 0.001, p = 0.046). There was no correlation between thiol, total thiol and disulphide ratios with Jak2 mutation, hemorrhage and thrombosis. A positive correlation was determined between thrombosis and thiol disulphide homeostasis (p = 0.058). The study results showed that thiol-disulphide homeostasis shifted to the proliferative side in ET, in which ineffective erythropoiesis was predominant. It is also known that platelets are more active i...